MS 006
Alternative Names: MS-006Latest Information Update: 27 Jan 2023
At a glance
- Originator Mabscale
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 22 Dec 2022 Preclinical trials in Unspecified in Russia (Parenteral) (Mabscale pipeline; December 2022)
- 22 Dec 2022 Mabscale anticipates approval for MS 006 for undisclosed indication before 2028 (Mabscale pipeline; December 2022)
- 22 Dec 2022 Mabscale anticipates launch for MS 006 in undisclosed indication in 2029 (Mabscale pipeline; December 2022)